News - Alpharadin

Filter

Current filters:

Alpharadin

Popular Filters

US NRC rules sites can procure radium-223 dichloride for Algeta/Bayer's prostate cancer candidate

14-01-2013

Norwegian drug developer Algeta (OSE: ALGETA) this morning announced that the US Nuclear Regulatory Commission…

AlgetaAlpharadinBayerNorth AmericaOncologyPharmaceuticalradium-223 dichlorideRegulation

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Bayer files prostate cancer drug Alpharadin in the EU

13-12-2012

German drug major Bayer (BAYN: DE) has filed for approval of its radiotherapeutic product Alpharadin…

AlgetaAlpharadinBayerEuropeOncologyPharmaceuticalRegulation

Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation

14-11-2012

German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant…

AlpharadinBayerCardio-vascularOncologyOphthalmicsPharmaceuticalResearchStivargaXarelto

Algeta prepares for Alpharadin US launch, opening US base

19-09-2012

In anticipation of the launch of Alpharadin (radium-223 chloride), for the treatment of cancer patients…

AlgetaAlpharadinBayerMarkets & MarketingNorth AmericaOncologyPharmaceutical

Algeta takes up option to co-promote Alpharadin in the USA

13-04-2012

Norwegian cancer therapeutics developer Algeta ASA (OSE: ALGETA) says that it has exercised its option…

AlgetaAlpharadinBayerLicensingMarkets & MarketingOncologyPharmaceutical

Four new drugs will change prostate cancer care, says US expert

19-02-2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer…

AlgetaAlpharadinAmgenBavarian NordicBayerJohnson & JohnsonOncologyPharmaceuticalProstvacXgevaZytiga

Bayer boasts four potential pipeline blockbusters

21-12-2011

German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

News briefs from breast cancer meeting

12-12-2011

In further news from the the San Antonio Breast Cancer Symposium (SABCS) that took place in Texas, USA…

AlgetaAlpharadinBayerGlaxoSmithKlineOncologyPharmaceuticalResearchTykerb

Positive first Phase III trial of an alpha-pharmaceutical, Bayer’s Alpharadin

26-09-2011

Until recently, options for patients with bone metastases from advanced prostate cancer have been very…

AlgetaAlpharadinBayerOncologyPharmaceuticalResearch

US FDA fast-tracks Bayer and Algeta’s prostate drug Alpharadin

23-08-2011

Germany’s Bayer (BAY: DE) said this morning that its investigational compound Alpharadin (radium-223…

AlgetaAlpharadinBayerNorth AmericaOncologyPharmaceuticalRegulation

Back to top